Results 121 to 130 of about 276,669 (295)

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, Volume 13, Issue 31, 4 June 2026.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma

Advanced Science, EarlyView.
A genome‐wide microRNA CRISPR screen identifies miR‐18a as a master regulator of cross‐resistance in melanoma. Loss of miR‐18a activates the AJUBA–YAP/Hippo axis to confer BRAFi resistance and enhances THBS1–CD47 interaction to impair CD8+ T cell immunity. hnRNP A1 is identified as an upstream regulator of miR‐18a processing.
Zhao Wang, Haotian Liu, Xueqi Wang, Jianjin Teng, Zihan Zheng, Jingya Zhang, Wanyi Xiao, Qian Liang, Jiaxin Li, Xiaomeng Jia, Xin Feng, Hongzhang Cui, Menghan Luo, Tielong Yang, Liuxing Wu, Ke Zhao, Weilong Yang, Mulin Jun Li, Dandan Huang, Jilong Yang   +19 more
wiley   +1 more source

Pharmacogenomics of the immunosuppressive agents

Japanese Journal of Clinical Immunology, 2002
Atsuo, Taniguchi, Wako, Urano, Eiichi, Tanaka, Yutaka, Kitamura, Masayuki, Saito, Hideto, Akama, Hishashi, Yamanak, Terunobu, Saito, Naoyuki, Kamatani   +8 more
openaire   +3 more sources

Live attenuated vaccines in patients receiving immunosuppressive agents. [PDF]

Pediatr Nephrol, 2023
Kamei K.
europepmc   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling‐Mediated Anti‐tumor Immunity

Advanced Science, EarlyView.
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang, Xi Dai, Shuaihu Li, Yingxue Chen, Yaxin Yu, Lin Wang, Kun Liu, Shuhan Lyu, Chongyang Li, Yihua Sun, Fei Li   +10 more
wiley   +1 more source

Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis. [PDF]

Front Immunol, 2023
Jiang N, Jin S, Yu C, Zhao J, Wang Q, Tian X, Li M, Zeng X.   +7 more
europepmc   +1 more source

Localized NF‐κB Inhibition Reduces Lipid Nanoparticle‐Associated Inflammation

Advanced Science, Volume 13, Issue 31, 4 June 2026.
Lipid nanoparticles (LNPs) activate NF‐κB and provoke inflammation that limits therapeutic delivery. By encapsulating selective NF‐κB inhibitors within LNPs, localized suppression of inflammatory signaling is achieved without compromising mRNA expression.
Carolann L. Espy, Jichuan Wu, Serena Omo‐Lamai, Liuqian Wang, Fengyi Dong, Aleksa Milosavljevic, Sarah O'Neill, Taylor Brysgel, Yufei Wang, Michael Zaleski, Emily Wolfe, Rhea Maheshwari, Manthan Patel, Dirk Trauner, Jia Nong, Zhicheng Wang, Jacob S. Brenner   +16 more
wiley   +1 more source